Introduction
============

Pain arising from inflammatory conditions is often treated with agents that inhibit the immune response, such as corticosteroids, or modulators of the inflammatory cascade, such as nonsteroidal antiinflammatory drugs (NSAIDs) ([@b44]). These drugs are associated with substantial adverse effects and risks with long-term use, ranging from gastrointestinal (GI) insult to opportunistic infections, and osteoporosis ([@b68]; [@b44]). While opioid receptor agonists have limited or, more likely, poorly understood antiinflammatory action, they remain useful effective analgesic agents in these conditions. However, respiratory depression, sedation, and constipation remain as dose-limiting side effects after systemic administration of this drug class. Tolerance, while not a common occurrence, can develop during long-term use ([@b153]; [@b102]; [@b104]; [@b73]).

The immune system is traditionally thought of as a contributor to inflammatory pain. However, a new analgesic role has been described for the immune system in the release of endogenous opioid peptides from immune cells within inflamed tissue ([@b162]). The benefit of peripheral immune-mediated opioid analgesia is targeted analgesia at the site of inflammation, and thus avoidance of side effects mediated by activation of opioid receptors in the central nervous system (CNS), or on peripheral organs such as the GI tract. Although immune cell-mediated endogenous opioid analgesia appears to challenge our current understanding of the role of the immune system in inflammation, it is likely that the two approaches to inflammatory pain treatment are not in contrast, but complementary. The role of the immune system in peripheral analgesia is likely to be delicately balanced, depending on whether the action of infiltrating cells is proinflammatory, proalgesic, or both; either predicted by the immune cell, or by the injury, or disease status. In situations where endogenous antinociception exceeds hyperalgesia mediated by immune cells, immuno-suppression or modulation of immune cell trafficking may increase pain ([@b65]).

A better understanding of the endogenous pathways and mechanisms involved in peripheral analgesia may not only enable us to target these pathways for novel antinociceptive approaches and avoid systemic side effects of opioid treatment, but it will also allow us to identify patients in whom immunosuppression may have detrimental effects on pain control and minimise the possible algesic effects of immunosuppression in these patients.

Opioid receptor distribution and mechanisms that mediate antinociception
========================================================================

Since their first characterization in 1973, 3 main opioid receptors, referred to as μ (MOR), δ (DOR), and κ (KOR), have been defined ([@b125]; [@b159]; [@b171]; [@b85]). These opioid receptors can exist as several splice variants, which are differentially expressed in the central and peripheral nervous systems as well as varying nonneuronal tissues, presumably due to different messenger ribonucleic acid (mRNA) processing as they are derived from the same gene ([@b1]; [@b85]).

Opioid receptor structure and function
--------------------------------------

Opioid receptors are prototypical G-protein coupled receptors belonging to the subfamily of rhodopsin receptors and consist of approximately 400 amino acids ([@b85]; [@b128]). On a molecular basis, they possess 7 α-helical transmembrane domains and an extracellular N-terminus with multiple glycosylation sites ([@b85]). MOR, DOR, and KOR are highly homologous to each other at the sequence and post-translational levels, with particularly high conservation in the regions spanning the transmembrane domains and intracellular loops ([@b82]; [@b2]; [@b85]; [@b128]). Divergence can be found at the N- and C-termini as well as the extracellular loops, accounting for the unique pharmacological properties of these receptors ([@b82]; [@b2]; [@b85]; [@b128]). Opioid receptors can couple to both pertussis toxin-sensitive and insensitive G-proteins, with coupling characteristics differing slightly between the receptor types. G-protein coupling of opioid receptors to their effectors can be direct or involve intermediate or other indirect effector pathways ([@b40]). Activation of inwardly rectifying K^+^ channels (GIRK^+^), inhibition of voltage-dependent Ca^2+^ channels as well as inhibition of adenylyl cyclase are direct G-protein-coupled effects of opioid receptor activation ([@b40]; [@b85]). Conversely, opioid receptors can activate phospholipase C (PLC), the mitogen-activated protein kinase (MAPK) cascade, and large conductance Ca^2+^-activated K^+^ channels by utilising other intermediary messenger systems ([@b40]; [@b85]). Modification of Ca^2+^ and K^+^ conductance by opioid receptors can lead to a decrease in neuronal excitability, a decrease in neuronal firing rate, and inhibition of neurotransmitter release ([@b40]; [@b85]). Functionally, opioid receptors have been implicated in regulation of pain, reinforcement, reward, neuroendocrine modulation, and alteration in neuro-transmitter release ([@b101]). The consequence of opioid receptor activation appears to be correlated closely with the anatomical location as well as expression levels of the opioid receptor subtypes ([@b101]).

Opioid receptor expression and function in the central nervous system
---------------------------------------------------------------------

Opioid receptors are widely and differentially distributed in the CNS. MOR, in particular, is widely distributed throughout the forebrain, midbrain, and hindbrain with greatest expression apparent in the neocortex, caudateputamen, nucleus accumbens, thalamus, hippocampus, amygdala, and nucleus tractus solitarius ([@b102], [@b101]). This distribution of the MOR is consistent with its suggested role in pain perception as well as sensorimotor integration. Conversely, KOR has been found to be expressed in moderate amounts in many brain areas, with greatest expression in the caudate putamen, nucleus accumbens, hypothalamus, amygdala, and neural lobe of the pituitary ([@b102], [@b101]). KOR has been implicated to be involved in feeding, pain perception, and neuroendocrine function. DOR is particularly highly expressed in olfactory related neural areas, the neocortex, caudate-putamen, nucleus accumbens, and amygdala while exhibiting limited binding in the thalamus, hypothalamus, and brainstem ([@b102], [@b101]). This distribution corresponds with the suggested involvement of DOR in motor as well as olfactory and cognitive functioning.

The functional consequences arising from these expression patterns of opioid receptors may affect many other physiological systems, which can have important implications for the clinical use of opioids, particularly in the unwanted side effects of systemically administered opioid receptor agonists. Many side effects arising from systemic administration of opioids are due to activation of central opioid receptors. Administration of MOR agonists has been linked to centrally mediated cardiovascular and renal effects ([@b102], [@b101]; [@b61]; [@b103]). Of particular relevance to the use of opioids as analgesics are respiratory depression mediated though activation of MOR and DOR in the brainstem, as well as KOR-mediated sedation; both of which can be dose-limiting side effects of systemic treatment with opioids ([@b153]; [@b102]).

Opioid receptor expression and function in the spinal cord and peripheral nervous system
----------------------------------------------------------------------------------------

Opioid-mediated analgesia is mediated by modulation of ascending and descending pain pathways ([@b102]; [@b176]; [@b123]). Accordingly, MOR, DOR, and KOR expression has been confirmed in dorsal root ganglia, the spinal cord, and trigeminal nucleus of the ascending pain pathway as well as the central Gray area, pontine, gigantocellulare, and intermediate reticular nuclei of the descending pain pathway, with predominantly MOR and KOR expression in the median raphe and raphe magnus ([@b102]). In the periaqueductal gray region and the nucleus locus coeruleus, opioid receptor agonists produce analgesia by disinhibiting descending fibres through inhibition of Gamma-Aminobutyric acid (GABA)-ergic neuronal inputs, which modulates other descending pathways in turn, such as noradrenergic neurons, to produce analgesia ([@b176]; [@b123]).

In addition to spinal and centrally mediated opioid analgesia, opioid receptors expressed on peripheral neurons can also contribute to antinociception. Numerous animal models and human clinical trials in support of this peripheral opioid analgesia have been described and will be discussed in greater detail in the next section. While targeting these peripheral mechanisms may provide analgesic strategies that can avoid some or all of the central side effects of systemic opioid agonists, some peripherally mediated side effects may remain problematic. This is a result of opioid receptor expression on peripheral nervous system neurons innervating peripheral organs such as the skin and GI tract ([@b7]; [@b52]; [@b14]; [@b69]). MOR and KOR have been found to be expressed in the stomach, duodenum, jejunum, ileum as well as proximal and distal colon, where their function is thought to include control of visceral pain, regulation of transit time of luminal contents, and mucosal transport of fluids and electrolytes ([@b7]; [@b52]; [@b48]; [@b69]; [@b59]). Accordingly, the adverse effect of systemic administration of opioid agonists on GI function is thought to arise primarily from modulation of the enteric pathways governing peristalsis by opioid receptor agonists ([@b7]; [@b52]; [@b69]). The effect of opioid receptor agonists on gut motility and secretion has been utilised clinically in the symptomatic management of diarrhea ([@b168]). Furthermore, opioid receptors may be involved in the modification of GI inflammation, possibly through the protein kinase C-mediated desensitization of chemokine receptors ([@b127]; [@b189]).

Opioid receptor expression and function in nonneuronal tissues
--------------------------------------------------------------

Opioid receptor protein and mRNA have also been described in several nonneuronal tissues such as vascular and cardiac epithelia as well as keratinocytes, although the significance of opioid receptor expression in these nonnociceptive tissues is less clear ([@b13]; [@b31]; [@b116]; [@b14]). MOR, DOR, and KOR are also expressed on various immune cells including lymphocytes and macrophages. Activation of the receptors have been reported to modulate immune function including the macrophage oxidative burst and cytokine production ([@b13]). Evidence for the expression of all 3 types of opioid receptors on immune cells stems from functional evidence suggesting that MOR, DOR, and KOR agonists can modulate immune cell function, and includes immunohistochemical and binding studies which verify the expression of MOR, DOR, and KOR on numerous immune cells ([@b13]). In addition, mRNA encoding for opioid receptors has been obtained from immune cells and supports the identification of opioid receptors expressed on immune cells as identical to neuronal receptors ([@b13]).

In summary, opioid receptor protein and mRNA have been described in both central and peripheral nervous systems as well as in several nonneuronal tissues. Activation of these differentially distributed receptors by systemic treatment with opioid receptor agonists not only causes analgesia, but can be directly correlated to clinically observed adverse effects such as respiratory depression, sedation, and constipation ([@b153]; [@b102], [@b101]; [@b52]; [@b176]; [@b61]; [@b69]; [@b123]; [@b103]).

Peripheral opioid receptors and their contribution to analgesia
===============================================================

Including centrally mediated effects, the potential that opioid receptors of the peripheral nervous system have for mediating effective analgesia is well documented. Common strategies to isolate the activation of peripheral opioid receptors include the administration of local, systemically inactive doses of opioids, and the use of hydrophilic opioids that do not readily penetrate the blood-brain barrier.

Animal models
-------------

In animal models of inflammatory pain, peripheral MOR, DOR, and KOR participate in the suppression of pain. In the inflammatory phase of the formalin test in rats, novel peripherally restricted μ-opioid agonists, administered subcutaneously, produced dose-dependent antinociception ([@b55]). This effect was reversed by the peripherally restricted antagonist naloxone methiodide, confirming the activation of peripheral MOR ([@b55]). The DOR agonist SNC80 produced dose-dependent antinociception in PGE~2~-induced hyperalgesia of the rat paw following subcutaneous administration ([@b122]). This effect was not observed after equivalent administration at a remote site, indicating that anti-nociception was delivered by peripheral DOR ([@b122]). KOR-selective opioid agonists, when administered subcutaneously to the paw, evoked potent dose-dependent increases in pain thresholds after Freund\'s complete adjuvant (FCA)-induced chronic inflammation, an effect antagonized by naloxone methiodide ([@b15]). In an animal model of inflammatory bowel disease, peripherally restricted κ-opioid agonists produced dose-dependent, peripherally antagonized reductions in visceromotor responses and afferent nerve activity, providing further evidence that peripheral KOR effects antinociception ([@b152]). In a single study using FCA-induced inflammation of the rat paw, locally acting MOR-, DOR-, and KOR-selective agonists delivered antinociception that was dose-dependent, stereospecific, and reversible by receptor specific antagonists ([@b166]). In addition to inflammatory pain, peripheral opioid receptors reportedly attenuate nociceptive responses in rats following thermal injury ([@b119]), and in animal models of uterine cervical distension ([@b144]), neuropathic pain ([@b126]; [@b173]; [@b121]), and nociceptive pain ([@b55]). Moreover, a technique involving viral-driven transfer and overproduction of proenkephalin A, a precursor for the endogenous opioid peptide enkephalin in trigeminal ganglion neurons, resulted in long lasting attenuation of allodynia in a rat model of neuropathic pain ([@b110]). Immunohistochemistry indicated that transgene-derived opioids were transported predominantly to the peripheral ends of primary sensory neurons. The abolition of transgene-derived antinociception by naloxone methiodide confirms that peripheral opioid receptors were responsible for the attenuation of allodynia in this model ([@b110]).

Human clinical studies
----------------------

Peripheral opioid receptor-mediated analgesia has also been demonstrated in controlled clinical studies. In experimental human pain models, administration of the peripherally restricted opioid agonists morphine-6-glucoronide (M6G) reduced hyperalgesia induced by freeze lesions and excessive muscle contraction, which was verified to be via peripheral action due to the absence of characteristic CNS effects ([@b170]). Patients with chronic pancreatitis reported reductions in abdominal pain following intravenous infusion with a peripherally restricted κ-opioid agonist ([@b50]). Similarly, the administration of locally acting opioids during knee and dental surgery significantly reduces postoperative pain and recovery time ([@b46]; [@b88]; [@b76]). Topical application of opioids for the treatment of painful skin ulcers and oral mucositis has also achieved effective relief of pain ([@b174]; [@b36]). Separate bioavailability studies indicate that therapeutic doses of opioids applied topically to skin ulcers are not readily absorbed into the blood and are therefore likely to act peripherally ([@b134]). Some clinical studies assessing the efficacy of locally acting opioids failed to show an improvement in pain intensity scores, but reported more subtle modifications such as increases in time to first analgesic request and a reduction in total analgesic requirement ([@b89]; [@b188]).

Despite overwhelming evidence that peripheral opioid receptors mediate effective analgesia, there is limited direct evidence describing opioid mechanisms at peripheral nerve endings. This is because elucidation of opioid receptor mechanisms has relied heavily upon techniques that utilize cultured neurons and other cellular expression systems. However, experiments in animal models using ion channel blockers indicate that opioid receptors on peripheral sensory nerve endings mediate analgesia partly through local activation of adenosine triphosphate (ATP)-sensitive K^+^ channels ([@b122]), and inhibition of L-type Ca^2+^ channels ([Figure 1](#fig1){ref-type="fig"}) ([@b156]).

![Proposed model for opioid receptor-mediated analgesia at peripheral terminals of primary sensory neurons. Activation of opioid receptors by endogenous or exogenous opioid agonists promotes G-protein coupling. Opioid receptor-coupled G-proteins directly activate inwardly rectifying K^+^ channels (GIRK^+^), inhibit voltage-dependent Ca^2+^ channels, and inhibit adenylyl cyclase (AC). Opioid receptors indirectly activate phospholipase C (PLC), the mitogen-activated protein kinase (MAPK) cascade, and large conductance Ca^2+^-activated K^+^ channels by utilizing other intermediary messenger systems.](tcrm0104-279-f1){#fig1}

Inflammation promotes opioid receptor mechanisms in the periphery
-----------------------------------------------------------------

An important determination from both animal and human studies is that peripherally acting exogenous opioids produce enhanced analgesia in the presence of inflammation. For example, in the rat paw model, locally acting opioid agonists significantly increase nociceptive thresholds to mechanical stimuli in inflamed tissue, but not in noninflamed tissue ([@b166]; [@b15]). In human studies, reports from dental surgery patients show that chronically inflamed tissue exhibits improved analgesic responses compared with acutely inflamed ([@b46]) and noninflamed tissue ([@b88]). These findings indicate that inflammation promotes opioid receptor mechanisms in the periphery.

Opioid receptor expression
--------------------------

In primary afferent neurons, opioid receptors are manufactured in the dorsal root ganglion (DRG) and are transported both centrally and peripherally by axonal transport ([@b63]). In the rat paw model, inflammation induces a significant increase in MOR in the DRG ([@b74]; [@b191]; [@b8]; [@b192]; [@b154]) and in peripheral nerves innervating the inflamed tissue ([@b63]; [@b116], [@b113]). In the spinal cord, there are reports of either no change ([@b8]; [@b154]), or increase in MOR expression ([@b74]; [@b113]); a discrepancy likely due to differences in disease state and the sensitivity of analytical techniques. Consistent with increased receptor expression, MOR mRNA levels are increased in both the DRG ([@b133]) and in the spinal cord ([@b99]), which supports the thesis that inflammation increases MOR synthesis. With respect to DOR and KOR, the effect of inflammation on receptor expression is less clear in the rat paw model. In separate studies with similar disease states, DOR expression is reported to decrease in DRG ([@b74]; [@b191]), increase in peripheral tissues ([@b63]), and both increase and decrease in the spinal cord ([@b74]; [@b33]). DOR mRNA levels reportedly remain unchanged in the DRG ([@b133]) and in the spinal cord ([@b99]). In independent studies, KOR expression has been found to both decrease and remain static in DRG ([@b74]; [@b191]), and remain constant in the spinal cord ([@b74]). A significant increase in KOR mRNA has been observed in the spinal cord of animals with peripheral inflammation ([@b99]). Adding further complexity; changes in KOR and DOR expression have also been reported in nonneuronal cells. More specifically, the expression of KOR and DOR have recently been shown to be decreased in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and osteoarthritis, particularly where inflammation was present ([@b155]). Upregulation of the KOR occurred through exposure to the specific KOR agonist U69593 ([@b155]), and while these changes occurred in cells isolated from patients and established in vitro, these observations could suggest that intra-articular or peripheral opioids may be useful in the management of these inflammatory conditions and could have an impact on pain states in these patients. Despite these apparently conflicting outcomes, DOR- and KOR-selective opioid agonists deliver potent antinociception in the inflamed rat paw model, suggesting the involvement of both DOR and KOR receptors in pain control during inflammation ([@b166]; [@b15]; [@b33]). In a separate inflammatory model, the inflamed mice intestine, MOR mRNA, and protein is upregulated in nerves innervating the gut ([@b129]). Furthermore, intestinal inflammation significantly increases DOR mRNA in peripheral nerves and in the spinal cord, and increases DOR and KOR receptor protein in peripheral nerves ([@b130]).

The mechanisms that affect opioid receptor upregulation during inflammation are not yet well understood, however, a number of recent studies provide insight into these mechanisms. The inflammatory mediator interleukin-6 (IL-6) strongly induces MOR, but not DOR transcription and translation in the human neuroblastoma cell line SHSY5Y ([@b19]). IL-6 evoked increases in MOR expression are mediated by the transcription factors signal transducers and activators of transcription 1 (STAT1) and transcription 3 (STAT3) ([@b19]). In vitro results with IL-6 are supported by findings that IL-6 knock out mice have reduced MOR levels in the grey matter of the midbrain compared with wild type individuals and exhibit reduced analgesic responses to morphine ([@b12]). Interleukin-4 stimulates MOR transcription in cultured immune cells and cultured neurons via transcription 6 (STAT6) activation of the MOR gene promoter ([@b83]). Furthermore, the proinflammatory cytokine tumor necrosis factor (TNF) induces MOR gene transcription, via the transcription factor nuclear factor κB (NFκB) in immune cells ([@b84]) and neurons ([@b18]). Nerve growth factor (NGF) is produced by peripheral tissues, particularly during inflammation ([@b107]), and is implicated in opioid receptor regulation. Transgenic mice that overexpress NGF show an increase in MOR and KOR expression and a decrease in DOR expression in DRG compared with wild type mice, and exhibit increased nociceptive thresholds ([@b195]). Further evidence that NGF influences opioid receptor function is provided by findings that intrathecal NGF restored opioid effectiveness in a rat model of neuropathic pain ([@b32]). In addition to the action of inflammatory cytokines and growth factors, the increased conduction of nociceptive signals that occurs during inflammation promotes opioid receptor transcription in sensory neurons, particularly during the early stages of inflammation ([@b133]). This was evidenced by blocking neuronal conduction with local anesthetic, which prevented the upregulation of MOR mRNA in the first 2 hours following induction of inflammation in the rat hind paw ([@b133]).

Opioid receptor efficacy
------------------------

The ability of opioid agonists to stimulate radiolabelled Guanosine 5′-Triphosphate (GTP) (\[^35^S\]GTP-γ-S) binding, provides a measure of G~i~/G~o~-protein coupling efficiency and the functional status of the opioid receptor ([@b172]). In DRG, but not spinal cord tissue, (D-Ala, N-Me-Phe, Gly-ol)-Enkephalin (DAMGO) stimulated (^35^S)GTP-γ-S binding is increased in animals with inflammation ([@b8]; [@b192]; [@b154]). These results may simply reflect the increase in opioid receptor density that occurs in DRG during inflammation, but nevertheless represent an improvement in the efficacy of the μ-opioid agonist DAMGO to stimulate opioid receptor G-protein coupling and may explain the increased antinociceptive effects of exogenous opioids in inflammatory conditions ([@b192]). Moreover, in cultured sensory neurons, the expression of MOR mRNA correlates directly with opioid-evoked inhibition of voltage-gated Ca^2+^ channels ([@b157]), which also suggests that the increase in opioid receptor expression evident during inflammation translates into a functional enhancement of opioid efficacy. Inflammation also alters the subcellular distribution of opioid receptors, mobilizing receptors towards the cell membrane ([@b33]), and disrupts the perineurial barrier surrounding sensory nerve fibres, providing opioid peptides better access to cell membrane receptors ([@b6]). Some inflammatory chemokines have been reported to desensitize opioid receptors on peripheral sensory neurons in vitro and to suppress opioid antinociception to the noninflamed periaqueductal gray region of the rat brain when administered before opioid treatment ([@b169]; [@b190]). These findings suggest that elements of the inflammatory process may, in isolation, impair opioid efficacy. However, opioids can exert a reciprocal desensitization of chemokine receptors ([@b189]), which is evidence of the complexity of the interaction between chemokine and opioid receptors; a relationship that is not fully understood. Furthermore, in the inflamed rat paw, inflammatory chemokines recruit opioid-containing polymorphonuclear cells. The blockade of these chemokines reduces peripheral opioid-mediated antinociception, which is evidence that chemokines promote opioid mechanisms ([@b22]). Tissue acidosis is another characteristic of inflammation that may affect opioid efficacy. Interstitial pH as low as 5.6 has been observed in various inflamed tissues ([@b49]; [@b72]; [@b180]; [@b158]; [@b5]). In NG108-15 cell membranes, acidic pretreatment increases opioid receptor-mediated inhibition of adenylyl cyclase by impairing GTPase activity ([@b151]). Further evidence that acidic inflammatory pH improves opioid efficacy is provided by studies using DRG neurons, which show that morphine inhibition of Ca^2+^ transients is enhanced at low extracellular pH ([@b78]).

Taken together, the changes that occur during inflammation contribute to enhanced opioid receptor expression and efficacy, particularly for MOR.

Immune cells contain opioid peptides
====================================

Endogenous opioid peptides
--------------------------

In mammals, pro-opiomelanocortin (POMC), proenkephalin (PENK) and pro-dynorphin (PDYN) are the precursor proteins from which the main endogenous opioid peptides β-endorphin (END), met-enkephalin (ENK), and dynorphin-A (DYN), respectively, are derived ([@b117]; [@b75]; [@b118]). Dynorphin A and B, which are derived from PDYN, have relatively high affinity for KOR, but also some affinity for MOR and DOR. ENK and leu-enkephalin are endogenous ligands derived from PENK that display preferential binding to DOR, lower affinity for MOR, and negligible binding to KOR ([@b132]). END, along with several nonopioid peptides, is derived from the precursor protein POMC and exhibits equipotent MOR and DOR binding while having lower affinity for KOR ([@b3]; [@b132]). Endomorphin-1 and endomorphin-2 are MOR-selective endogenous peptides of so far unknown origin that have been found in distinct regions of rat brain as well as primary neurons and the spinal cord ([@b105]; [@b187]; [@b150])

Opioid peptides in nonneuronal cells
------------------------------------

The role of END, ENK, and DYN has been described in detail for both central and peripheral antinociceptive pathways ([@b132]). Interestingly, nonneuronal tissues have also been described to contain opioid peptides that may contribute to peripheral antinociception.([@b29], [@b30]; [@b145]; [@b53]; [@b90]; [@b115]). Opioid peptides have been shown to be expressed in keratinocytes ([@b79]), and it has been suggested that these cells may be an important source of endogenous opioid receptor agonists. In particular, activation of both the endothelin-B and cannabinoid CB2 receptors have been shown to elicit analgesia in vivo through release of END from keratinocytes ([@b79]; [@b71]) This occurred in models where pain was induced either through injection of endothelin-1, or a noxious thermal stimulus, and may highlight that local release of opioid peptides can achieve anatomically specific analgesia ([@b79]; [@b71]).

Immune cells are of particular interest with respect to nonneuronal cell types involved in endogenous analgesic mechanisms. Expression of opioid peptides by immune cells have been extensively studied and have been shown to express both full-length and truncated mRNA encoding for the precursor proteins POMC, PENK, and PDYN. Moreover, the respective opioid peptides END, ENK, and DYN have been described in many immune cells of rodent and human origin ([@b93]; [@b160]; [@b194]; [@b120]; [@b27]; [@b141]; [@b165]; [@b64]; [@b131]; [@b175]; [@b145]; [@b91]; [@b29], [@b30]; [@b94]; [@b77]; [@b17]; [@b16]; [@b115]). Originally, the role of these opioid peptides was thought to consist of the regulation of local immune function through the neuroendocrine axis ([@b93]; [@b120]; [@b141]; [@b100]; [@b77]; [@b17]). This was supported by the observation that immune cells express opioid receptors ([@b34]). In addition, functional evidence verified that opioids can modulate immune function, including mitogen-induced proliferation, antibody production, and natural killer (NK) activity ([@b100]). An additional role for these peptides emerged with the observation that opioid peptides released locally from immune cells can act on opioid receptors expressed on peripheral neurons to exert an antihyperalgesic effect in inflamed tissue ([@b165]; [@b145], [@b146]; [@b29], [@b30]; [@b28]; [@b116], [@b115]; [@b137]; [@b138]).

Immune cells express opioid peptides and their precursor proteins
-----------------------------------------------------------------

The mechanism proposed for this immune-derived peripheral antinociception involves recruitment of immune cells to local inflamed areas, where they release endogenous opioid peptides upon stimulation with proinflammatory mediators such as interleukin 1β (IL-1β) and corticotrophin-releasing factor (CRF) as well as sympathetic mediators such as noradrenaline ([@b165]; [@b145], [@b146]; [@b29], [@b30]; [@b28]; [@b116], [@b115]; [@b137]; [@b16]; [@b138]). Numerous leukocytes, including lymphocytes, macrophages, monocytes, and human peripheral blood mononuclear cells, have been reported to contain these opioid peptides ([@b93]; [@b160]; [@b194]; [@b120]; [@b27]; [@b141]; [@b165]; [@b64]; [@b131]; [@b175]; [@b145]; [@b91]; [@b29], [@b30]; [@b94]; [@b77]; [@b17]; [@b16]; [@b115]). Generally, both precursor protein as well as opioid peptide expression appear to be increased in immune cells from inflamed tissue or mitogen-stimulated cells compared with quiescent leukocytes ([@b160]; [@b194]; [@b27]; [@b141]; [@b64]; [@b175]; [@b29], [@b30]; [@b94]; [@b115]). Regulation of POMC in lymphocytes has been reported to be dynamic with both mRNA and opioid peptide levels increased in mitogen-stimulated cells, while POMC expression in macrophages was of a more constitutive nature ([@b94]). In addition, the predominant opioid-containing cell type appears to be dynamically regulated depending on the progression of the inflammatory cascade ([@b137]). Increased complexity is additionally suggested by an observation that immune cells from inflamed lymph nodes contain relatively less opioid peptides compared with cells from noninflamed lymphatic tissue, while at the same time opioid peptide content in local inflamed tissue is increased ([@b29]). This observation is consistent with a model of peripheral opioid antinociception whereby immune cells migrate to inflamed tissue in a site directed manner, release these opioid peptides, and then return to lymphatic tissues depleted of peptide ([Figure 2](#fig2){ref-type="fig"}) ([@b29]).

![Endogenous opioid peptides are released by immune cells to reduce inflammatory pain. Adhesion molecules expressed on immune cells and inflamed endothelium coordinate the migration of circulation immune cells into inflamed tissue. The proinflammatory mediators corticotropin-releasing factor (CRF) and interleukin-1β (IL-1β), as well as the sympathetic neurotransmitter, noradrenaline, stimulate immune cells to secrete their opioid peptides. These peptides activate opioid receptors located on the peripheral ends of sensory neurons and effectively reduce inflammatory pain. Immune cells, devoid of their opioid contents, then continue their passage to neighbouring lymph nodes.](tcrm0104-279-f2){#fig2}

Opioid peptides involved in peripheral antinociception
------------------------------------------------------

END and ENK have been proposed to be the most important opioid peptides involved in immune-derived opioid antinociception. Antibodies to both END and ENK could reverse the antihyperalgesic effect observed after release of these peptides from immune cells was stimulated using CRF or IL-1β ([@b165]; [@b30]). Although DYN and PDYN levels were generally reported to be low, this opioid peptide is likely to be of some significance in mediating peripheral antinociception as antiDYN has been reported to inhibit IL-1β-induced analgesia ([@b131]; [@b30]). In addition, expression of both the opioid peptide and its precursor were observed to be increased significantly in immune cells during inflammation, although absolute levels were low ([@b30]). The exact role of DYN in peripheral antinociception remains to be elucidated.

All three opioid peptides have been proposed to be contained within vesicular structures similar to those observed in neurons. The release of these endogenous opioid receptor ligands is Ca^2+^ dependent and can be evoked by stimulation with high K^+^ ([@b100]; [@b29], [@b30]). Ultrastructural studies have confirmed the presence of END in secretory granules in macrophages, monocytes, granulocytes, and lymphocytes within immune cells from inflamed tissue ([@b115]). These granules were grouped in small vesicular structures within the cytoplasm, while larger vesicles were observed to possess extended processes ready for exocytosis ([@b115]).

Numerous papers have reported that immune cells contain opioid peptides and increasing functional evidence is being accumulated to suggest that these endogenous opioid receptor ligands can be released in local inflamed tissues by leukocytes to alleviate inflammatory hyperalgesia ([@b93]; [@b29]; [@b77]; [@b16]; [@b115]). In early inflammation, the degree of antinociception evoked through these locally released opioid peptides relies heavily upon the number of opioid receptors expressed in these tissues rather than the number of opioid peptide-containing immune cells recruited to the inflamed site ([@b23]). Analgesia, mediated through the release of endogenous opioid peptides, may become increasingly important as the number of opioid receptors expressed increases with the progression of inflammation ([@b192]; [@b23]).

Inflammation and the migration of circulating leukocytes
========================================================

Leukocyte migration and adhesion molecules
------------------------------------------

For opioid-containing immune cells to elicit antinociception by releasing their endogenous opioid peptide load in local inflamed tissue, these cells must first migrate to these tissues.

"Homing" of immune cells to inflamed sites is a complex process and involves numerous inflammatory mediators, chemoattractants, and adhesion molecules. The extra-vasation of leukocytes into inflamed tissue is enabled by the interaction of adhesion molecules expressed on leukocytes and vascular endothelium. These adhesion molecules comprise the carbohydrate binding selectins, immunoglobulins (Ig) such as ICAM and PECAM, and the integrin family of α and β subunit heterodimers ([@b178]). The upregulation of adhesion molecules and the engagement of leukocytes in the extravasation process are promoted by various inflammatory mediators and chemoattractants such as interleukin-1 (IL-1), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), thrombin, histamine, RANTES ([R]{.ul}egulated upon [A]{.ul}ctivation [N]{.ul}ormal [T]{.ul} cell [E]{.ul}xpressed and [S]{.ul}ecreted), monocyte chemotactic peptide (MCP), and macrophage inflammatory peptides (MIP) ([@b161]; [@b178]; [@b177]). Passing leukocytes are initially tethered by the action of selectins. P- and E-selectins are expressed on vascular endothelium and L-selectins are constitutively expressed on leucocytes ([@b25]). Once loosely tethered by selectins, leukocytes roll along the inflamed endothelium, which promotes the upregulation of leukocyte integrins and further adhesion ([@b161]; [@b26]). Leukocyte integrins bind to the immunoglobulins expressed on endothelium; a firm interaction that results in the arrest of circulating leukocytes ([@b161]; [@b26]). Leukocyte arrest is followed by diapedesis of the leukocyte, through relaxed endothelial junctions and into the inflamed tissue. These processes enable a targeted and leukocyte subset selective migration at the site of inflammation ([@b161]; [@b26]).

Presentation of opioid-containing immune cells in inflamed tissue
-----------------------------------------------------------------

In the rat paw model, the induction of inflammation with FCA results in a significant increase in opioid-expressing leukocytes in the inflamed tissue ([@b29]; [@b137]). Assessment with fluorescence-activated cell staining indicates that approximately 20% of immune cells that infiltrate inflamed tissue contain endogenous opioid peptides ([@b137]; [@b97]). At the early stages of inflammation, opioid-expressing immune cells are predominantly from a neutrophil lineage, representing 66% of opioid-containing cells. At later stages, monocytes and macrophages are prominent, representing 73% of opioid-expressing leukocytes ([@b137]; [@b149]). Other studies have shown that activated lymphocytes are the prevalent opioid-containing immune cell type in the later stages of inflammation ([@b29]; [@b116]). This discrepancy is likely due to the use of different immunoreactive staining procedures. Opioid-expressing cells roughly reflect general immune cell type representation at different stages of inflammation ([@b137]).

Immune-derived opioids reduce inflammatory pain
===============================================

Stress-induced analgesia during inflammation in peripheral tissue
-----------------------------------------------------------------

Stressful stimuli trigger potent analgesia mediated by endogenous opioid systems in the CNS ([@b184]). The response to stress is characterized by stimulation of the hypothalamic--pituitary--adrenocortical axis resulting in the sequential secretion of CRF and adrenocorticotrophic hormone (ACTH); activation of the sympathetic nervous system, which releases noradrenaline from the adrenal medulla and sympathetic nerve endings; and the activation of endogenous opioid systems in the CNS ([@b184]). In rats with inflammation of the hind paw however, stress-induced analgesia is mediated predominantly by endogenous opioids that bind to peripheral opioid receptors to effectively reduce inflammatory pain ([@b163]).

A common technique for evoking stress-induced analgesia is cold water swim stress (CWS). In the rat paw model, CWS induces sudden antinociception that manifests as significant increases in pain thresholds in the inflamed paw ([@b163]). This analgesia is most potent immediately following the insult and subsides within 10 to 15 minutes ([@b163]). The antinociceptive effect of CWS is dose-dependently reversible by opioid receptor antagonists, which suggests that antinociception is opioid receptor-mediated. At the early stages of inflammation (6 hours after induction with FCA), CWS-evoked antinociception is completely blocked by systemically acting doses of naloxone and partially blocked by peripherally selective antagonists, which demonstrates a central and peripheral component ([@b98]). However, as inflammation becomes chronic (described in this study as 4 days post FCA), peripherally selective antagonists completely abolish CWS-evoked anti-nociception, indicating that analgesia is mediated exclusively by opioid receptors on peripheral sensory nerves innervating the inflamed paw ([@b98]). The use of antibodies against specific endogenous opioid peptides and selective opioid receptor antagonists reveal that at the early stages of inflammation, the peripheral component of CWS-evoked analgesia is mediated by END, ENK, and DYN, which activate MOR, DOR, and KOR ([@b98]). At later stages of inflammation (as observed at 4 days post FCA), antinociception is delivered wholly by END, activating peripheral MOR and DOR ([@b163]; [@b98]).

Endogenous opioids are released from leukocytes
-----------------------------------------------

CWS-evoked analgesia in the rat paw depends on the local action of CRF and noradrenaline, evidenced by reversal following local injection of CRF receptor antagonists and adrenergic receptor antagonists respectively ([@b146]; [@b16]). CRF, noradrenaline, and the proinflammatory cytokine, IL-1β, evoke the release of opioid peptides from leukocytes. Immune cell suspensions extracted from rats with inflamed hind paws exhibit receptor-specific and concentration-dependent opioid release when exposed to CRF, noradrenaline, and IL-1β ([@b146]; [@b29], [@b30]; [@b16]; [@b115]). CRF induces the release of END, ENK, and DYN ([@b30]); noradrenaline releases END ([@b16]; [@b115]); and IL-1β releases END and DYN ([@b30]). An upregulation of receptors for these mediators on immune cells participating in an inflammatory response indicating that inflammation consolidates opioid release mechanisms ([@b193]; [@b114]). Separate administration of CRF, noradrenaline, and IL-1β to the inflamed rat paw evokes potent dose-dependent and pharmacologically reversible analgesia ([@b16]; [@b145]). This antinociceptive effect is the result of local action at the inflamed site as equivalent doses administered systemically are ineffective ([@b145]; [@b16]). Antibodies against opioid peptides and opioid receptor antagonists abolish the analgesic effects of CRF, noradrenaline, and IL-1β, confirming that the observed analgesia is mediated by endogenous opioids that activate opioid receptors ([Figure 2](#fig2){ref-type="fig"}) ([@b145]; [@b16]). Further evidence supporting immune cells as the source of opioid peptides is provided by findings that the administration of CRF, noradrenaline, and IL-1β into noninflamed paws does not evoke an antinociceptive effect ([@b145]; [@b16]). The degree of analgesia induced by exposure to CWS increases proportionally with the presentation of opioid-containing immune cells in the inflamed hind paw ([@b137]; [@b98]).

Impaired immune cell function leads to impaired endogenous analgesia
====================================================================

Numerous studies have reported that impaired immune cell function is associated with diminished opioid analgesia, which is consistent with the model where immune cells release opioid peptides in inflamed tissue to elicit antinociception ([@b165]; [@b131]; [@b145]; [@b96], [@b98]; [@b112]; [@b20], [@b21], [@b22]; [@b65]). This effect has been described for immunomodulatory agents that affect immune cell trafficking as well as numerous treatments that compromise the functional integrity of leukocytes ([@b165]; [@b131]; [@b145]; [@b96], [@b98]; [@b112]; [@b20], [@b21], [@b22]; [@b65]).

Immune cell trafficking
-----------------------

Fucoidin, which binds to selectins and blocks leukocyte "rolling", has been reported to impair analgesia induced by CWS and CRF ([@b96]). This impaired antinociception was paralleled by a decrease in END content as well as a decrease in the number of END-containing immune cells in inflamed tissue ([@b96]). Similarly, intracellular adhesion molecule-1 (ICAM-1) has been found to be upregulated in inflamed tissue and appears to contribute to the recruitment of opioid-containing cells to these local microenvironments as antiICAM-1 decreased CWS- and CRF-induced analgesia ([@b97]). Other adhesion molecules, including P-selectin, platelet-endothelial adhesion molecule-1 (PECAM-1), and L-selectin, are also upregulated in inflammation, and these increased expression levels correlate with increased END levels ([@b112]). However, while the exact role of these adhesion molecules in endogenous opioid analgesia remains to be elucidated, results indicate that PECAM-1 is not required for endogenous opioid analgesia ([@b95]). The same study confirmed functional integrity of selectins and integrins as essential for immune-derived antinociception ([@b95]).

In contrast to adhesion molecule-mediated leukocyte trafficking, chemokine-mediated recruitment of polymorphonuclear cells may target opioid-containing leukocytes more specifically, as immune cells containing opioid peptides have been reported to be mostly chemokine receptor (CXCR2)-positive ([@b22]). Accordingly, a blockade of the keratinocyte-derived chemokine (KC) and macrophage inflammatory protein-2 (MIP-2) decreased the number of opioid-containing leukocytes in inflamed tissue and abolished CRF-induced antinociception in the inflamed rat paw ([@b22]).

Effect of immunosuppressants on immune-derived antinociception
--------------------------------------------------------------

Further evidence for the importance of the functional integrity of opioid-containing immune cells in endogenous analgesia stems from the observation that the immunosuppressant Cyclosporine A (CsA) can dose-dependently block CWS-, IL-1- and CRF-induced peripheral analgesia ([@b165]; [@b145]; [@b65]). The reduced paw pressure threshold that has been observed in inflamed paws of CsA-treated animals was mirrored by a decrease in the number of infiltrating lymphocytes and could be reversed by administration of activated lymphocytes ([@b65]). Nonspecific immunosuppression induced by whole body irradiation also decreased stress-induced antinociception in inflamed paws, while more specific depletion of monocytes/ macrophages by liposomal clodronate similarly decreased stress-induced endogenous opioid antinociception without affecting exogenous opioid analgesia ([@b131]; [@b20]).

Clinical evidence for association between impaired immune function and increased pain
-------------------------------------------------------------------------------------

Reduced END content in immune cells has clinically been reported in numerous painful conditions, including arthritis, Crohn\'s disease, fibromyalgia, migraine, and tension headache ([@b181], [@b182]; [@b124]). There is little evidence to suggest that opioid content in circulating immune cells significantly contributes to analgesia. A reduction in opioid content of these cells may compromise the local delivery of opioid peptides to inflamed tissues by migrating immune cells and thus impair endogenous analgesic mechanisms in these patients. In line with this observation, pain associated with disease or inflammation may be increased in immunocompromised patients ([@b109]). A positive correlation between immunosuppression and increased pain has been reported, and in AIDS patients in particular, a decreased CD4+ count appears to be a risk factor for developing painful pathologies such as polyneuropathy ([@b86]; [@b183]; [@b87]; [@b67]; [@b148]). These observations highlight the importance of the immune system and release of endogenous opioid peptides for antinociception.

Immunosuppressive effects of exogenous opioids
==============================================

Exogenous opioids such as morphine remain the most effective treatment for acute and chronic pain. There is evidence suggesting that opioids have an immunosuppressive action as well as clinically apparent side effects, such as respiratory depression, constipation, tolerance, and dependence ([@b135]). The implications of opioid-evoked immunosuppression are particularly relevant during the postoperative period when pain and susceptibility to infection are high; for sufferers of chronic pain and drug users who administer opioids for extended periods; and for patients with immunosuppressive disease such as AIDS, transplant patients, and the elderly, who are predisposed to opportunistic infections.

Evidence for opioid-evoked immunosuppression
--------------------------------------------

Much of the data that suggests opioids have immunosuppressive effects come from epidemiological studies with drug users. These individuals are reported to have markedly increased incidence of skin and soft tissue infections, pulmonary infections, endocarditis, skeletal infections, malaria, and viral hepatitis, although it is accepted that interpretation of these findings is confounded by compromised lifestyle practices associated with this population ([@b70]; [@b147]; [@b135]). In healthy nonaddicted individuals, morphine treatment for obstetric procedures resulted in the reactivation of herpes simplex virus ([@b41]), supporting an immunosuppressive action. Animal models of opioid administration and infection show increased mortality rates in opioid treated animals with experimentally-induced sepsis and *Toxoplasma gondii* infection, reversible by opioid receptor antagonists ([@b37]; [@b142]). Morphine-dependent swine, challenged with herpes virus, exhibited enhanced pneumonia secondary to herpes virus infection, although these animals also exhibited a paradoxical decrease in clinical signs associated with neurological disease ([@b136]). In mice inoculated with *Streptococcus pneumonia*, chronic morphine treatment delayed neutrophil recruitment, increased bacterial burden, and increased mortality ([@b179]). Various commonly measured immune parameters are significantly suppressed following opioid exposure in drug users, healthy human subjects, and animal models. These include suppressed NK cell activity ([@b35]; [@b185]; [@b143]), macrophage phagocytic function ([@b140]), cytokine production ([@b11]; [@b143]), lymphocyte proliferation ([@b11]; [@b143]), and spleen and thymus weight and cellularities ([@b54]; [@b11]). In experiments with opioid receptor knock out mice, mutant mice did not exhibit the abnormal immune parameters that were observed in wild type mice following chronic morphine treatment, indicating that opioid receptors mediate morphine-induced immunosuppression ([@b56]). These findings collectively indicate that exposure to exogenous opioids impairs resistance to infection and suppresses immune function.

Centrally mediated opioid-evoked immunosuppression
--------------------------------------------------

There is evidence that opioid-evoked immunosuppression is mediated by opioid receptors in the CNS. Systemic administration of morphine significantly reduced lymphocyte proliferation ex vivo but the peripherally restricted N-methylmorphine did not, suggesting that a central mechanism mediates immunosuppression ([@b66]). Furthermore, the central administration of both morphine and N-methylmorphine effectively inhibited lymphocyte proliferation. Several studies have identified the periaqueductal gray (PAG) matter of the mesencephalon as a site of morphine-induced opioid receptor-mediated immunosuppression. Injection of morphine into the PAG is reported to suppress ex vivo macrophage nitric oxide (NO) production, NK cell activity, lymphocyte proliferation, and leukocyte IL-2 production ([@b57]; [@b58]). In rats with FCA-induced inflammation of the hind paw, concomitant intrathecal morphine administration selectively attenuated the presentation of END-positive leukocytes in the inflamed paw without affecting total immune cell numbers ([@b149]). This result led to the hypothesis that arresting pain transmission in the CNS signals a reduced need for immune-derived opioid peptides in the inflamed tissue ([@b149]), and provides further evidence for centrally mediated opioid immuno-modulation.

Opioids activate receptors on immune cells and suppress immune activity
-----------------------------------------------------------------------

In addition to centrally-mediated immunosuppression, the expression of opioid receptors on immune cells suggest that opioids may modulate immune function by direct action on these cells ([@b13]). This is supported by findings that in vitro exposure to morphine resulted in concentration-dependent and antagonist-reversible inhibition of macrophage phagocytic function ([@b140]. Opioids also directly suppress macrophage production of proinflammatory cytokines IL-1, IL-6, TNF-α ([@b4]), and impair monocyte chemotaxis in response to cytokines MIP-1α, MCP-1, and RANTES, through opioid receptor-mediated heterologous desensitization of chemokine receptors ([@b60]). Morphine directly upregulates immune cell Fas receptors that trigger apoptosis of the cell when activated by the ligand FasL ([@b186]). In this way, morphine administered in vivo apparently primes leukocytes for elimination by apoptosis and suppresses the immune response ([@b186]).

Opioid stimulation of immune cell function
------------------------------------------

In contrast to findings that opioids exert an immunosuppressive action, there is evidence that some opioids, particularly endogenous opioid peptides, stimulate aspects of immune function. In vitro experiments demonstrate that endogenous opioids such as END and ENK enhance human NK cell activity ([@b106]); increase IL-2 production in the lymphoid cell line EL-4 ([@b10]); increase leukocyte surface expression of compliment and immunoglobulin receptors ([@b108]); increase leukocyte oxidative burst activity ([@b108]); and augment macrophage tumoricidal activity ([@b62]). In vivo administration of ENK reportedly improves the survival rate of mice infected with herpes simplex virus and inhibits tumor growth ([@b51]). The immunostimulatory properties of endogenous opioids suggest that their release by immune cells in inflamed tissue not only controls pain but also stimulates immune function.

Clinical implications for pain control
======================================

Systemic administration of opioids is clinically associated with numerous side effects. While immunomodulatory effects of opioids can have clinical implications as described above, most dose-limiting adverse events, such as respiratory depression, sedation, and tolerance are mediated through activation of central opioid receptors ([@b80]). A logical consequence is the attempt to target peripheral opioid receptors more specifically. Numerous studies have demonstrated that peripheral opioids can provide effective analgesia ([@b166]; [@b88]; [@b173]; [@b55]; [@b122]). The immunosuppressive effect of opioid receptor agonists may contribute to peripheral opioid analgesia as it has been speculated that a local anti-inflammatory effect contributed to prolonged analgesia produced by intra-articular morphine ([@b162]).

Strategies to target peripheral opioid receptors specifically include the development and use of peripherally active opioid receptor agonists, such as loperamide, asimadoline, and frakefamide, which can usually penetrate the blood brain barrier poorly, or local administration of centrally active opioids as well as treatments aimed at reducing degradation of locally released peptides ([@b9]; [@b42]; [@b38]; [@b188]; [@b111]). Peripherally selective opioids have met with some clinical success, although most work has been carried out with peripherally selective KOR agonists such as fedotozine ([@b43]). Despite promising pilot studies, both centrally mediated adverse events as well as peripheral side effects arising from systemic administration of opioid agonists, including constipation, could not be completely excluded ([@b43]; [@b50]; [@b139]). Thus, research aimed at the development of opioid receptor agonists that do not cross the blood brain barrier and are peripherally selective, but can be administered orally to achieve peripheral opioid analgesia remains ongoing. Targeted delivery of opioids locally to the site of pain could avoid the problems of peripherally selective opioid receptor agonists which retain the potential to cause side effects mediated through opioid receptor activation in the periphery. Side effects include nausea and vomiting arising from stimulation of opioid receptors in the chemo-receptor trigger zone, and constipation from opioid modulation of GI function. Accordingly, while local administration of centrally active opioid receptor agonists can be effective, limiting factors are problems arising from the required routes of administration, such as intra-articular injection ([@b81]).

Historically, immunosuppression has been used as an analgesic strategy in numerous inflammatory conditions such as rheumatoid arthritis ([@b92]). In light of recent evidence suggesting that endogenous opioid peptides are released locally from immune cells to elicit antihyperalgesia ([@b165]), current clinical practices are likely to be challenged as our understanding of the complex interaction between the immune system and pain control increases. The role of the immune system in analgesia is likely to be delicately balanced depending on whether infiltrating cells are proinflammatory and proalgesic or their major role is an antiinflammatory and analgesic one. In situations where endogenous antinociception exceeds hyperalgesia mediated by immune cells, immuno-suppression of modulation of immune cell trafficking might increase pain. This hypothesis is supported by the observation that intra-articular naloxone lead to an increase in postoperative pain and analgesic consumption ([@b164]).

Approaches could target immune cell trafficking to increase immune-mediated endogenous opioid anti-nociception and thus achieve analgesia, which lacks the side effects usually associated with systemic administration of opioid receptor agonists. The immigration of opioid-containing immune cells could be specifically encouraged by utilising chemokines or adhesion molecules. An increase in antinociceptive and decrease in proalgesic cell migration would complement current immunosuppressive treatment strategies. Endogenous opioid analgesia could be further enhanced by increasing infiltrating analgesic cell numbers or by increasing opioid peptide production in these cells. While stimulation of immune cell production using granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) has not met with the expected increase in endogenous analgesia to date, gene therapy targeting endogenous opioid peptide production in peripheral neurons has had some success and may be applied to opioid-peptide containing immune cells in future ([@b24]; [@b21]; [@b47]; [@b39]).

A further approach to enhance peripheral opioid analgesia includes inhibition of degradation of endogenous opioid peptides. Using this approach, enhanced anti-nociception was achieved in a rodent model of thermal pain by administration of enkephalin-degrading enzyme inhibitor prodrugs ([@b38]). In addition to enhanced antinociception, an additional benefit of this approach to achieve analgesia is the relative lack of immunosuppressive effects of endogenous opioid peptides, which would render these compounds superior to exogenous opioids in certain patient groups. Accordingly, modifications that would enable dosing with these endogenous peptides by eliminating instability and poor bioavailability of the compounds could be the beginning of a new class of analgesic opioid agonists ([@b45])

The clinical implications of the complex interactions between the immune system and pain control are especially pertinent to immunocompromised patients. An impairment in immune cell function may lead to decreased endogenous antinociception and thus increased pain ([@b109]). In AIDS patients in particular, undertreatment of pain has been reported to be common ([@b86]), which gives greater significance to our understanding of how endogenous opioid antinociception might be altered in immunocompromised patient groups. Future studies directed at investigating changes in immune cell trafficking and endogenous opioid analgesia in these patients may provide clinical strategies to more effectively treat pain.
